

Jon Arnason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11385157/publications.pdf>

Version: 2024-02-01

43
papers

2,449
citations

567281

15
h-index

377865

34
g-index

43
all docs

43
docs citations

43
times ranked

2984
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	1.4	66
2	Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 2294-2308.	13.7	273
3	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021, 35, 1064-1072.	7.2	25
4	Case Report: Refractory Cryptosporidiosis after CAR T-Cell Therapy for Lymphoma. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 651-653.	1.4	4
5	Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 212-216.	1.0	2
6	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, , .	7.2	14
7	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2020, 136, 3051-3055.	1.4	15
8	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet, The</i> , 2020, 396, 839-852.	13.7	1,224
9	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2020, 4, 925-929.	5.2	8
10	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology,the</i> , 2019, 6, e419-e428.	4.6	60
11	Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia. <i>Acta Haematologica</i> , 2019, 141, 222-224.	1.4	2
12	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	1.3	3
13	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology,the</i> , 2018, 5, e170-e180.	4.6	44
14	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	1.4	30
15	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1791-1801.	1.4	130
16	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <sc>MUC</sc>1. <i>British Journal of Haematology</i> , 2017, 176, 929-938.	2.5	34
17	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2304-2314.	4.1	10
18	Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7Âyears. <i>British Journal of Haematology</i> , 2016, 172, 412-419.	2.5	119

#	ARTICLE	IF	CITATIONS
19	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. <i>Science Translational Medicine</i> , 2016, 8, 368ra171.	12.4	140
20	Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 387-387.	1.4	2
21	Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 4192-4192.	1.4	25
22	Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. <i>Blood</i> , 2016, 128, 621-621.	1.4	16
23	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016, 128, 641-641.	1.4	10
24	A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2016, 7, 26346-26360.	1.8	12
25	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4175-4175.	1.4	0
26	MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs. <i>Blood</i> , 2016, 128, 2871-2871.	1.4	1
27	Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells. <i>Blood</i> , 2016, 128, 703-703.	1.4	0
28	A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma. <i>Blood</i> , 2016, 128, 4484-4484.	1.4	0
29	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. <i>Blood</i> , 2015, 126, 354-362.	1.4	31
30	MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2473-2473.	1.4	2
31	Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. <i>PLoS ONE</i> , 2015, 10, e0130518.	2.5	53
32	Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression. <i>Blood</i> , 2014, 124, 2072-2072.	1.4	3
33	MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 808-808.	1.4	0
34	Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 2303-2303.	1.4	0
35	Inhibition of Phosphorylation of ERK in CLL Cells Pre-Treatment Correlates Best with Response to Dasatinib, Fludarabine, and Rituximab for Patients with Relapsed CLL. <i>Blood</i> , 2014, 124, 3636-3636.	1.4	18
36	Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and Are Dependent on MUC1 Expression. <i>Blood</i> , 2014, 124, 226-226.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1. <i>Blood</i> , 2014, 124, 3378-3378.	1.4	0
38	MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. <i>Cancer Research</i> , 2013, 73, 5569-5579.	0.9	49
39	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients. <i>Blood</i> , 2013, 122, 3928-3928.	1.4	7
40	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013, 122, 86-86.	1.4	8
41	Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential. <i>Blood</i> , 2013, 122, 127-127.	1.4	0
42	Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL. <i>Blood</i> , 2013, 122, 5300-5300.	1.4	0
43	Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma. <i>Immunotherapy</i> , 2012, 4, 1043-1051.	2.0	9